FDA black box warnings: characteristics of drug classes and adverse effects

Black box warnings represent the most severe U.S. Food and Drug Administration (FDA) safety alerts.Currently, they are fragmented across individual product labels and not systematically accessible at the level of drugs or drug classes.This study provides a comprehensive overview of drugs with black box warnings and identifies class-and categoryspecific patterns of adverse effects, aiming to support risk-benefit assessments and rational treatment.626 drugs across 250 drug classes were identified as carrying black box warnings.Drug classes were unevenly distributed, with many classes represented by a single drug, while a small number of large classes accounted for a substantial proportion of entries, e.g., -opioid receptor (MOR) agonists, cyclooxygenase (COX) inhibitors, angiotensin-converting enzyme (ACE) inhibitors or kinase inhibitors.Across all drugs, 1016 adverse effect category listings were identified, demonstrating that multiple serious risks are frequently combined within a single boxed warning.Cardiac and cardiovascular adverse effects are the most prevalent category (18.7%), followed by immunologic and allergic reactions (11.4%), beside drug category-specific patterns.The standardized adverse effect count ranged from 1.1 in endocrine system drugs to 2.1 in cytotoxic treatments, indicating marked differences in the density and variety of serious adverse effects between drug categories.Black box warnings reveal pronounced heterogeneity across drugs, but show consistent, mechanism-related patterns at the level of drug classes and categories.These patterns allow estimation of probable, high-risk adverse effects and risk profiles.A structured, drug-class-based overview of black box warnings can improve awareness of safety risks and support rational prescribing.